The estimated Net Worth of Wendy F Dicicco is at least $211 Thousand dollars as of 20 August 2024. Ms. Dicicco owns over 2,567 units of EyePoint Pharmaceuticals Inc stock worth over $81,929 and over the last 18 years she sold EYPT stock worth over $129,184. In addition, she makes $0 as Director at EyePoint Pharmaceuticals Inc.
Wendy has made over 10 trades of the EyePoint Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently she bought 2,567 units of EYPT stock worth $19,997 on 20 August 2024.
The largest trade she's ever made was selling 4,400 units of EyePoint Pharmaceuticals Inc stock on 23 December 2016 worth over $129,184. On average, Wendy trades about 774 units every 85 days since 2007. As of 20 August 2024 she still owns at least 9,967 units of EyePoint Pharmaceuticals Inc stock.
You can see the complete history of Ms. Dicicco stock trades at the bottom of the page.
Wendy F. DiCicco CPA serves as Director of the Company. Ms. DiCicco currently serves on the Board of Directors of Carmell Therapeutics, a private biotechnology company producing plasma-based bioactive materials for accelerated healing in bone and connective tissue injuries, and is a Financial, Executive and Board Advisory Consultant for several emerging growth companies. She previously served as President and Chief Operating Officer of Camber Spine Technologies where she significantly expanded the Company's operations, infrastructure and commercial organization. Prior to Camber Spine, she held several Chief Financial Officer roles at Nuron Biotech, Quench USA, Globus Medical and Kensey Nash Corporation. Her career started in public accounting at Deloitte & Touche. Ms. DiCicco received a B.S. in accounting from Philadelphia College of Textiles and Science and is a licensed CPA. She is also an appointed Board Leadership Fellow and Corporate Governance Fellow of the National Association of Corporate Directors (NACD).
Wendy DiCicco is 52, she's been the Director of EyePoint Pharmaceuticals Inc since 2019. There are 18 older and no younger executives at EyePoint Pharmaceuticals Inc. The oldest executive at EyePoint Pharmaceuticals Inc is Goran Ando, 71, who is the Independent Chairman of the Board.
Wendy's mailing address filed with the SEC is C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, WATERTOWN, MA, 02472.
Over the last 7 years, insiders at EyePoint Pharmaceuticals Inc have traded over $67,100,515 worth of EyePoint Pharmaceuticals Inc stock and bought 21,910,863 units worth $111,404,456 . The most active insiders traders include Healthcare Partners, L.P.Ew..., Asset Management, Lp Chen B..., and Ye Liu. On average, EyePoint Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $1,746,068. The most recent stock trade was executed by Goran Ando on 21 August 2024, trading 5,000 units of EYPT stock currently worth $39,750.
psivida corp., (nasdaq: psdv) (asx: pva) headquartered in watertown, ma, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. psivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, durasert™ and biosilicon™. the injectable, sustained release micro-insert iluvien® for the treatment of chronic diabetic macula edema (dme), licensed to alimera sciences, inc., has received marketing authorization in austria, france, germany, portugal, the u.k. spain, and italy. iluvien for dme has recently been approved in the us. psivida plans to institute pivotal phase iii clinical trials for the treatment of posterior uveitis with the same micro-insert as iluvien for dme. an investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. psivida's two fda-approved products, retisert®
EyePoint Pharmaceuticals Inc executives and other stock owners filed with the SEC include: